New hope for kidney stone sufferers: Longer-Acting drugs may offer better prevention
NCT ID NCT06111885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two long-acting drugs, indapamide and chlorthalidone, to the standard short-acting drug hydrochlorothiazide for preventing calcium kidney stones. About 99 adults who have had at least two kidney stones in the past 10 years will participate. The goal is to see if the longer-acting drugs reduce stone-forming substances in urine more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY STONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inselspital, Department of Nephrology and Hypertension
RECRUITINGBern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••